Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Stability Study Protocol for 0.1% Estradiol Type a Medicated Article (estraqua?) - Research & Related Other Project Information: Section 7 Project Summary/abstract This Type a Stability Project Is Required by the Fda Center for Veterinary Medicine to Complete a Portion of the CMC Technical Section of the New Animal Drug Application. This Project Will Evaluate Stability of Inad 012-884 (type a Medicated Article, 0.1% Estradiol (estraqua®)) Under Ambient (25 ± 2 °C / 60 ± 5% RH) and Accelerated (40 ± 2 °C / 75 ± 5% RH) Conditions Over Several Months. Appearance, Estradiol Level, Particle Size Distribution and Loss Upon Drying Will Be Evaluated Over Time. the Proposed Inad Will Be Administered in Feed (at a Dosing Rate of 5 PPM) to American Eels (anguilla Rostrata) in a Recirculating Aquaculture System (ras). Information From This Stability Study Will Substantially Contribute to Full Fda Approval.
Committed
$250,000
Paid out
$175.0K
70%
Committed, not yet paid
$75.0K
30%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…